These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 15153664)

  • 1. Effects of fluvastatin in type 2 diabetic patients with hyperlipidemia: reduction in cholesterol oxidation products and VCAM-1.
    Guan JZ; Murakami H; Yamato K; Tanabe J; Matsui J; Tamasawa N; Suda T
    J Atheroscler Thromb; 2004; 11(2):56-61. PubMed ID: 15153664
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of fluvastatin in patients with non-insulin-dependent diabetes mellitus and hyperlipidemia.
    Knopp RH; Frohlich J; Jokubaitis LA; Dawson K; Broyles FE; Gomez-Coronado D
    Am J Med; 1994 Jun; 96(6A):69S-78S. PubMed ID: 8017470
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of fluvastatin on hyperlipidemia after renal transplantation.
    Tokumoto T; Tanabe K; Ishida H; Shimmura H; Ishikawa N; Goya N; Akiba T; Toma H
    Transplant Proc; 2004 Sep; 36(7):2141-4. PubMed ID: 15518777
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and tolerability of fluvastatin and bezafibrate in patients with hyperlipidemia and persistently high triglyceride levels.
    Spieker LE; Noll G; Hannak M; Lüscher TF
    J Cardiovasc Pharmacol; 2000 Mar; 35(3):361-5. PubMed ID: 10710119
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-oxidative effect of fluvastatin in hyperlipidemic type 2 diabetic patients.
    Miwa S; Watada H; Omura C; Takayanagi N; Nishiyama K; Tanaka Y; Onuma T; Kawamori R
    Endocr J; 2005 Apr; 52(2):259-64. PubMed ID: 15863958
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Time-of-intake (morning versus evening) of extended-release fluvastatin in hyperlipemic patients is without influence on the pharmacodynamics (mevalonic acid excretion) and pharmacokinetics.
    Fauler G; Abletshauser C; Erwa W; Löser R; Witschital K; März W
    Int J Clin Pharmacol Ther; 2007 Jun; 45(6):328-34. PubMed ID: 17595890
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A review of current clinical findings with fluvastatin.
    Garnett WR
    Am J Cardiol; 1996 Sep; 78(6A):20-5. PubMed ID: 8875971
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The lipoprotein and coronary atherosclerosis study (LCAS): lipid and metabolic factors related to atheroma and clinical events.
    Herd JA
    Am J Med; 1998 Jun; 104(6A):42S-49S. PubMed ID: 9684851
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of fluvastatin of hyperlipidemia in renal transplant recipients: a prospective, placebo-controlled study.
    Türk S; Yildiz A; Tükek T; Akkaya V; Aras U; Türkmen A; Uras AR; Sever MS
    Int Urol Nephrol; 2001; 32(4):713-6. PubMed ID: 11989571
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Fluvastatin in the treatment of hyperlipoproteinemia, initial experience].
    Ceska R
    Vnitr Lek; 1996 Aug; 42(8):533-6. PubMed ID: 8967021
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fluvastatin: a review of its use in lipid disorders.
    Langtry HD; Markham A
    Drugs; 1999 Apr; 57(4):583-606. PubMed ID: 10235694
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the effect of two HMG CoA reductase inhibitors on LDL susceptibility to oxidation.
    Portal VL; Moriguchi EH; Vieira J; Schio S; Mastalir ET; Buffé F; Bortolini EB; Brüch RS; Rodrigues R
    Arq Bras Cardiol; 2003 Feb; 80(2):156-61, 150-5. PubMed ID: 12640509
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fluvastatin increases LDL particle size and reduces oxidative stress in patients with hyperlipidemia.
    Yoshino G; Hirano T; Kazumi T; Takemoto M; Ohashi N
    J Atheroscler Thromb; 2003; 10(6):343-7. PubMed ID: 15037823
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of fluvastatin in patients with non-insulin-dependent diabetes mellitus and hyperlipidemia: preliminary report.
    Knopp RH; Frolich JJ
    Am J Cardiol; 1994 May; 73(14):39D-41D. PubMed ID: 8198023
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficiency of 1-year treatment with fluvastatin in hyperlipidemic patients with nephrotic syndrome.
    Matzkies FK; Bahner U; Teschner M; Hohage H; Heidland A; Schaefer RM
    Am J Nephrol; 1999; 19(4):492-4. PubMed ID: 10460940
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of once-daily vs twice-daily dosing with fluvastatin, a synthetic reductase inhibitor, in primary hypercholesterolemia.
    Insull W; Black D; Dujovne C; Hosking JD; Hunninghake D; Keilson L; Knopp R; McKenney J; Stein E; Troendle AJ
    Arch Intern Med; 1994 Nov; 154(21):2449-55. PubMed ID: 7979841
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and efficacy of fluvastatin in hyperlipidemic patients with chronic renal disease.
    Yasuda G; Kuji T; Hasegawa K; Ogawa N; Shimura G; Ando D; Umemura S
    Ren Fail; 2004 Jul; 26(4):411-8. PubMed ID: 15462110
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of fluvastatin, a new HMG CoA reductase inhibitor, in elderly hypercholesterolaemic women.
    Baggio G; De Candia O; Forte PL; Mello F; Andriolli A; Donazzan S; Valerio G; Milani M; Crepaldi G
    Drugs; 1994; 47 Suppl 2():59-63. PubMed ID: 7517835
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Effects of fluvastatin on plasma lipid abnormalities in hemodialysis patients with chronic renal failure].
    Tanaka M; Itoh K; Matsushita K; Kitamura K; Nonoguchi H; Tomita K
    Nihon Jinzo Gakkai Shi; 2002 May; 44(4):402-8. PubMed ID: 12073626
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lipid-lowering therapy with fluvastatin inhibits oxidative modification of low density lipoprotein and improves vascular endothelial function in hypercholesterolemic patients.
    Inoue T; Hayashi M; Takayanagi K; Morooka S
    Atherosclerosis; 2002 Feb; 160(2):369-76. PubMed ID: 11849660
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.